1. Babjuk M et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol 2017; 71: 447-61.
2. Alfred Witjes J et al. Updated 2016 EAU guidelines on muscle-nvasive and metastatic bladder cancer. Eur Urol 2017; 71: 462-75.
3. Retz M et al. S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms.
4. Robert Koch-Institut. Krebs in Deutschland für 2013/2014., 2017.
5. Kassouf W et al. Follow-up in non-muscle-invasive bladder cancer – International Bladder Cancer Network recommendations. Urol Oncol 2016; 34: 460-8.
6. Drejer D et al. Comparison of white light, photodynamic diagnosis, and narrow-band imaging in detection of carcinoma in situ or flat dysplasia at transurethral resection of the bladder: The DaBlaCa-8 study. Urology 2017; 102: 138-42.
7. Burger M et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data. Eur Urol 2013; 64: 846-54.
8. Zheng C et al. Narrow band imaging diagnosis of bladder cancer: Systematic review and meta-analysis. BJU Int 2012; 110: E680-7.
9. Brausi M et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies. Eur Urol 2002; 41: 523-31.
10. Mariappan P et al. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010; 57: 843-9.
11. Karl A et al. [Non-muscle invasive bladder cancer : Current aspects of diagnostics, local therapy options and the update of the 2016 WHO classification]. Urologe A 2016; 55: 1247-58.
12. Migliari R. et al. Thulium laser endoscopic en bloc enucleation of nonmuscle-invasive bladder cancer. J Endourol 2015; 29: 1258-62.
13. Muto G et al. Thulium:yttrium-aluminum-garnet laser for en bloc resection of bladder cancer: Clinical and histopathologic advantages. Urology 2014; 83: 851-5.
14. Kramer MW et al. En bloc resection of urothelium carcinoma of the bladder (EBRUC): A European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol 2015; 33: 1937-43.
15. Fritsche HM et al. Water-jet-aided transurethral dissection of urothelial carcinoma: A prospective clinical study. J Endourol 2011; 25: 1599-603.
16. Nagele U et al. Waterjet hydrodissection: First experiences and short-term outcomes of a novel approach to bladder tumor resection. World J Urol 2011; 29: 423-7.
17. Hautmann RE et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: Long-term results in 1100 patients. Eur Urol 2012; 61: 1039-47.
18. Bruins HM et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: A systematic review. Eur Urol 2014; 66: 1065-77.
19. Gschwend JE et al. Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02). J Clin Oncol 2016; 34 (suppl): ASCO 2016, Abstract #4503.
20. Bhindi B et al. Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: A pathologic stage-matched analysis. Eur Urol 2017; 72: 660-4.
21. Schmid SC et al. Prognostic value of computed tomography before radical cystectomy in patients with invasive bladder cancer: Imaging predicts survival. World J Urol 2016; 34: 569-76.
22. Kulkarni GS et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 2017; 35: 2299-305.
23. Hanna N et al. Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol 2018; 36: 88.e1-e9.
24. Kretschmer A et al. Prognostic features for objectively defined urinary continence after radical cystectomy and ileal orthotopic neobladder in a contemporary cohort. J Urol 2017; 197: 210-5.
25. Kretschmer A et al. Prognostic features for quality of life after radical cystectomy and orthotopic neobladder. Int Braz J Urol 2016; 42: 1109-20.
26. Seiler R et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 2017; 72: 544-54.
27.  Moschini M et al. Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. World J Urol 2018; 36: 639-44
28. Bellmunt J et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015-26.
29. Balar AV et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. Lancet Oncol 2017; 18: 1483-92.
30. Sharma P et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016; 17: 1590-8.
31. Balar AV et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet 2017; 389: 67-76.